Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Lowered to Sell at Wall Street Zen

Recursion Pharmaceuticals (NASDAQ:RXRX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their target price for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Bank of America dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Down 6.7%

Shares of NASDAQ:RXRX opened at $2.94 on Friday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -1.99 and a beta of 0.97. Recursion Pharmaceuticals has a 1-year low of $2.91 and a 1-year high of $7.18. The company’s fifty day moving average is $3.74 and its two-hundred day moving average is $4.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business had revenue of $35.54 million during the quarter, compared to analyst estimates of $24.56 million. During the same period in the previous year, the business posted ($0.53) EPS. The company’s quarterly revenue was up 671.7% on a year-over-year basis. Equities analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30. Following the sale, the chief executive officer directly owned 2,262,085 shares in the company, valued at approximately $7,577,984.75. The trade was a 1.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ben R. Taylor sold 21,383 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $4.18, for a total transaction of $89,380.94. Following the completion of the sale, the chief financial officer directly owned 761,550 shares of the company’s stock, valued at approximately $3,183,279. This represents a 2.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 511,063 shares of company stock valued at $2,135,702. Company insiders own 8.43% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth $16,040,000. Bank Pictet & Cie Europe AG acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $7,954,000. ARK Investment Management LLC boosted its stake in Recursion Pharmaceuticals by 1.7% during the third quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock valued at $163,702,000 after buying an additional 556,868 shares in the last quarter. Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 10.3% during the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after acquiring an additional 3,708,975 shares during the period. Finally, Rafferty Asset Management LLC grew its holdings in Recursion Pharmaceuticals by 110.6% during the third quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock worth $3,661,000 after acquiring an additional 394,022 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.